Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Preclinical Evaluation of Antisense Oligonucleotide Therapy for RNA Polymerase III-Related Leukodystrophy Using Striatal Organoids
EF 2023-24
Résumé
RNA polymerase III-related leukodystrophy (POLR3-HLD) is an autosomal recessive disorder associated with a spectrum of severity. POLR3-HLD is caused by mutations in genes encoding RNA polymerase III (Pol III) subunits. Pol III is responsible for transcription of many short non-coding RNAs. POLR3-HLD is associated with three different forms of disease: mild, typical, and severe. The severe form affects infants and progresses very quickly, causing severe disabilities and premature death. It is associated with compound heterozygous mutations in the POL III subunit A (POLR3A) gene. On one copy, a nonsense mutation causes premature termination, leading to targeting of the transcript for nonsense mediated decay. The mutation on the second allele causes leaky alternative splicing of exon 14 or exon 13 and 14 as well as some normal transcript. Our group has demonstrated that neurons are most affected in the severe form of POLR3-HLD, with significant neuronal loss in the basal ganglia. How transcriptional defects lead to neuronal loss in severe POLR3-HLD is currently unknown. We hypothesize transcriptional defects are toxic to a type of neurons present in the striatum, medium spiny neurons (MSN). To model POLR3-HLD, we will use region-specific brain organoids. For severe POLR3-HLD, we propose the use of striatal organoids. This will allow us to better analyze the neuronal deficits observed in patients. Developing the first representative disease model will allow us to test the preclinical feasibility of antisense oligonucleotide (ASO) therapy. There are currently several therapies approved or under investigation using ASOs in neurological diseases. We propose to develop specific ASOs for exon inclusion and toxic RNA degradation to avoid damage to MSNs.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506054
Name
Gauthier Samuel
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Preclinical Evaluation of Antisense Oligonucleotide Therapy for RNA Polymerase III-Related Leukodystrophy Using Striatal Organoids
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antisense Oligonucleotides; Hypomyelination; Ipscs; Leukodystrophy; Organoids; Pediatric; Polr3-Hld; Rna Polymerase Iii; Splice Switching; Striatum
Abstract
RNA polymerase III-related leukodystrophy (POLR3-HLD) is an autosomal recessive disorder associated with a spectrum of severity. POLR3-HLD is caused by mutations in genes encoding RNA polymerase III (Pol III) subunits. Pol III is responsible for transcription of many short non-coding RNAs. POLR3-HLD is associated with three different forms of disease: mild, typical, and severe. The severe form affects infants and progresses very quickly, causing severe disabilities and premature death. It is associated with compound heterozygous mutations in the POL III subunit A (POLR3A) gene. On one copy, a nonsense mutation causes premature termination, leading to targeting of the transcript for nonsense mediated decay. The mutation on the second allele causes leaky alternative splicing of exon 14 or exon 13 and 14 as well as some normal transcript. Our group has demonstrated that neurons are most affected in the severe form of POLR3-HLD, with significant neuronal loss in the basal ganglia. How transcriptional defects lead to neuronal loss in severe POLR3-HLD is currently unknown. We hypothesize transcriptional defects are toxic to a type of neurons present in the striatum, medium spiny neurons (MSN). To model POLR3-HLD, we will use region-specific brain organoids. For severe POLR3-HLD, we propose the use of striatal organoids. This will allow us to better analyze the neuronal deficits observed in patients. Developing the first representative disease model will allow us to test the preclinical feasibility of antisense oligonucleotide (ASO) therapy. There are currently several therapies approved or under investigation using ASOs in neurological diseases. We propose to develop specific ASOs for exon inclusion and toxic RNA degradation to avoid damage to MSNs.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gauthier, Samuel
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~